More Chimeric Therapeutics Limited news
Chimeric Therapeutics LimitedASX: CHM

Successful Completion of First Patient Cohort Phase 1 Trial

Apr 21, 2021 at 11:06 PM EDT · Issued by Chimeric Therapeutics Limited

Filed with ASX · Apr 21, 2021 at 11:06 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/successful-completion-of-first-patient-cohort-phase-1-trial

Chimeric Therapeutics Limited on 6ix

Story so far

  • Successful Completion of Dosing in First Patient CohortMar 18, 2021

Earlier from Chimeric Therapeutics

  • Successful Completion of Dosing in First Patient CohortMar 17, 2021

Later from Chimeric Therapeutics

  • Appendix 4C - quarterlyApr 23, 2021
  • Second Dose Cohort Initiated in CLTX CAR T Phase 1 TrialMay 23, 2021
  • Chimeric licenses novel solid tumor CAR T therapy from PennJul 27, 2021
  • IND clearance received from US FDA for CHM 1101Aug 19, 2021
  • Chimeric Appoints Jennifer Chow as CEO & MDAug 30, 2021
All Chimeric Therapeutics news releases↗

Follow Chimeric Therapeutics into a list and get an email when it puts out news.

Follow Chimeric Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer